comparemela.com

Latest Breaking News On - குழு பகிர் - Page 6 : comparemela.com

Virbac: 2020 current operating income showed strong growth (+37 6% at constant rates and scope), reflecting the excellent evolution of revenue (+5 7% at constant rates and scope) and a sharp decrease in expenses

Virbac: 2020 current operating income showed strong growth (+37.6% at constant rates and scope), reflecting the excellent evolution of revenue (+5.7% at constant rates and scope) and a sharp decrease in expenses +3.2% 1 2 13.8% 8.4 +21.6% 1 137.5 5 +9.5% 1 The change at constant exchange rates and scope is the organic growth, excluding the impact of exchange rate changes, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the exchange rate in effect for the previous financial year), and excluding the impact of changes in scope (i.e. excluding Sentinel over both periods).

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results March 04, 2021 16:42 ET | Source: Cellectis Inc. Cellectis Inc. New York, New York, UNITED STATES Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r B-ALL presented in oral session at 2020 ASH Annual Meeting Partner Allogene Therapeutics presented initial results from Phase 1 ALPHA clinical study of licensed ALLO-501 in r/r NHL at 2020 ASCO Annual Meeting and from Phase 1 UNIVERSAL clinical study of licensed ALLO-715 in r/r MM at 2020 ASH Annual Meeting

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.